Close
Top Videos
Top Searches
Moods
Black Lives Matter
Chill
Christmas
Commute
Energy boosters
Feel-Good
Focus
Party
Pride
Romance
Sad
Sleep
Workout
Genres
African
Arabic
Blues
Bollywood & Indian
Christian & Gospel
Classical
Country and Americana
Dance and electronic
Decades
Family
Folk and acoustic
Hip-hop
Indie and alternative
J-Pop
Jazz
K-Pop
Latin
Mandopop & Cantopop
Metal
Pop
R&B and Soul
Reggae and Caribbean
Rock
Soundtracks and musicals
Unmet needs in DLBCL: frontline therapy, CAR-T optimization, and clinical trial inclusion
01:55
|
Download MP3
Related Videos
5:11
iStopMM: the psychological effects of MGUS screening and changes to clinical presentation of myeloma
3:08
Welcome to the Video Journal of Hematology & Hematological Oncology 🎥🩸
5:21
Challenges in the treatment and management of ET and the need to improve therapeutic approaches
1:42
The future of CLL treatment: aiming for long-lasting remission
1:31
Frontline treatment for CLL: the changing paradigm
6:54
Biomarker-guided treatment of CLL in the chemo-free era
1:36
The use of outpatient cilta-cel in the treatment of multiple myeloma
3:02
The role of asparaginase in the treatment of ALL
1:01
Treatment-free remission after second-generation TKI treatment in CML
3:48
Trials of interest in newly diagnosed myeloma presented at IMS 2024
0:44
Early detection and interception across hematological cancers
2:13
Personalizing the timing of SCT in patients with myelofibrosis
5:40
Recommendations for biomarker analysis in CLL: updates from ERIC 2024
1:15
The diagnosis and management of MDS/MPN with neutrophilia (atypical CML)
2:59
The tests that are needed to make a definitive diagnosis of CLL
1:14
Promising novel agents in AML: menin inhibitors
1:25
Prognostic and predictive biomarkers in CLL and their potential in guiding treatment decisions
3:40
Master class in transplantation and hematology: highlights
0:47
Advice for physicians when managing bispecific antibody treatment for patients with myeloma
1:55
Unmet needs in DLBCL: frontline therapy, CAR-T optimization, and clinical trial inclusion
5:11 3:08 5:21 1:42 1:31 6:54 1:36 3:02 1:01 3:48 0:44 2:13 5:40 1:15 2:59 1:14 1:25 3:40 0:47 1:55
